Endotoxin removal is one of the most persistent bottlenecks in bringing therapeutic bacteriophages to market. Produced by the outer membrane of Gram-negative bacteria, endotoxins (lipopolysaccharides, or LPS) can trigger severe immune reactions in patients if not reduced to ultra-low levels. For a Contract Development and Manufacturing Organization (CDMO), especially one producing phage therapies at GMP […]
Category: Phage Bioengineering
Pseudomonas Phage Manufacturing: Why CDMO Expertise Matters
Pseudomonas phages—viruses that specifically infect and destroy Pseudomonas aeruginosa—are emerging as a leading tool in the fight against multi-drug resistant (MDR) bacteria. This opportunistic pathogen is a notorious cause of chronic lung infections in cystic fibrosis patients, life-threatening burn wound infections, and stubborn hospital-acquired infections. Unlike traditional antibiotics, a well-characterized Pseudomonas phage can selectively target pathogenic P. aeruginosa strains while […]
What It Takes to Be a Top-Notch Phage CDMO
Bacteriophages—viruses that infect and kill bacteria—are experiencing a renaissance as powerful tools in the fight against antibiotic resistance, as well as innovators in microbiome engineering and probiotic enhancement. Once relegated to niche academic interest, phages now promise precision antibacterials that leave beneficial microbes intact, live biotherapeutic products that modulate our gut ecosystems, and bio-control agents […]